Skip to content
Nonprofiteer
← All organizations

GLOBAL ALLIANCE FOR TB DRUG DEVELOPMENT INC

EIN 13-4128413 NEW YORK, NY

Browse the largest nonprofits in New York

Revenue 2024
$63,732,557
Expenses 2024
$61,508,783

Program services were 88.5% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

As filed

Subsection
03
NTEE code
H80
Classification
8000
Street
80 PINE STREET 20TH FLR

These codes are the IRS's own and are shown exactly as filed. What each one means is in the Business Master File documentation (opens in a new tab).

Mission and programs · 2024

Mission

TB ALLIANCE IS A NOT-FOR-PROFIT ORGANIZATION DEDICATED TO THE DISCOVERY, DEVELOPMENT AND DELIVERY OF BETTER, FASTER-ACTING AND AFFORDABLE TUBERCULOSIS DRUGS THAT ARE AVAILABLE TO THOSE WHO NEED THEM.

Activities or mission (Part I)

TO ACCELERATE THE DISCOVERY & DEVELOPMENT OF NEW DRUGS TO FACILITATE THE CONTROL OF TUBERCULOSIS THROUGHOUT THE WORLD AND THE ACCESSIBILITY OF THESE DRUGS TO THE GLOBAL COMMUNITY.

  • RESEARCH AND DEVELOPMENT - TB ALLIANCE IS A NOT-FOR-PROFIT PRODUCT DEVELOPMENT PARTNERSHIP (PDP), UNIQUELY POSITIONED TO LEVERAGE A GLOBAL NETWORK OF PUBLIC AND PRIVATE PARTNERS TO MOST EFFICIENTLY ADVANCE TB DRUG DEVELOPMENT. A PDP BUILDS PARTNERSHIPS BETWEEN THE PUBLIC, PRIVATE, ACADEMIC, AND PHILANTHROPIC SECTORS TO DRIVE THE DEVELOPMENT OF NEW PRODUCTS FOR UNDERSERVED MARKETS. PDPS RETAIN DIRECT MANAGEMENT OVERSIGHT OF THEIR PROJECTS, THOUGH MUCH OF THE LABORATORY AND CLINICAL WORK IS DONE THROUGH EXTERNAL RESEARCH FACILITIES AND CONTRACTORS. WE COMBINE THE RESEARCH AND DEVELOPMENT EXPERTISE OF OUR STAFF WITH THE SKILLS AND RESOURCES OF OUR PARTNERS TO HARNESS THE MOST PROMISING SCIENCE WHEREVER IT MAY EXIST AROUND THE WORLD. THIS MODEL MINIMIZES COSTS, INCLUDING OVERHEAD AND INVESTMENTS IN INFRASTRUCTURE, WHILE OPTIMIZING SCIENTIFIC CAPABILITY TO SPEED NEW TB DRUG DEVELOPMENT. OUR BUSINESS MODEL AND DIVERSE PARTNERSHIPS ALLOW TB ALLIANCE TO LEVERAGE ADDITIONAL PARTNER SERVICES FOR EVERY DOLLAR INVESTED IN ITS PROGRAMS. NC-009 - NC-009 IS A PAN-PHASE 2 CLINICAL TRIAL INCORPORATING ELEMENTS OF PHASE 2A, B, AND C TO EVALUATE THE SAFETY AND EFFICACY OF A COMBINATION OF A NEW EXPERIMENTAL COMPOUND, TBAJ-876, WITH PRETOMANID AND LINEZOLID, COMPONENTS OF TB ALLIANCE'S BPAL REGIMEN. THIS REGIMEN HAS THE POTENTIAL TO SHORTEN AND IMPROVE TREATMENT FOR BOTH DRUG-SENSITIVE AND DRUG-RESISTANT FORMS OF TB. RESULTS FROM PRECLINICAL AND PHASE 1 STUDIES WERE PRESENTED AT THE 2023 UNION CONFERENCE ON LUNG HEALTH AND SHOWED THAT THE NEW COMPOUND, TBAJ-876, WHEN COMPARED WITH BEDAQUILINE (A TB MEDICINE IN THE SAME DRUG CLASS), ELIMINATED TB BACTERIA FASTER AND HAD A POTENTIALLY SAFER PROFILE. NC-009 WILL TEST DIFFERENT DOSES OF TBAJ-876 IN COMBINATION WITH PRETOMANID AND LINEZOLID AGAINST THE CURRENT STANDARD OF CARE FOR DRUG-SENSITIVE TB - ISONIAZID, RIFAMPICIN, PYRAZINAMIDE, AND ETHEMBUTOL (HRZE). ANOTHER ARM OF THE TRIAL WILL ALSO TEST PRETOMANID AND LINEZOLID IN COMBINATION WITH BEDAQUILINE (BPAL), A REGIMEN NOW RECOMMENDED BY THE WORLD HEALTH ORGANIZATION TO TREAT SOME FORMS OF DR-TB, AGAINST DRUG-SENSISTIVE TB. THE STUDY ENROLLED APPRXIMATELY 300 PARTICIPANTS WITH DRUG-SENSITIVE TB AT 21 CLINICAL TRIAL SITES IN FIVE COUNTRIES: GEORGIA, PHILIPPINES, SOUTH AFRICA, TANZANIA, AND UGANDA. Q203 - TELACEBEC (Q203) IS A FIRST-IN-CLASS DRUG CANDIDATE AGAINST MYCOBACTERIUM TUBERCULOSIS INFECTION. Q203 TARGETS CYTOCHROME BC1 COMPLEX AND SHOWS POTENT ACTIVITY AGAINST MULTIDRUG-RESISTANT TUBERCULOSIS (MDR-TB). Q203 HAS ALSO BEEN FOUND EFFECTIVE AGAINST BURULI ULCER (MYCOBACTERIUM ULCERANS), A CHRONIC, NECROTIZING DISEASE THAT AFFECTS SKIN AND SOMETIMES BONE AND CAN LEAD TO PERMANENT DEFORMITY AND LONG-TERM DISABILITY, AND LEPROSY (MYCOBACTERIUM LEPRAE). IN 2023, TB ALLIANCE IN-LICENSED Q203 FROM QURIENT, A CLINICAL-STAGE BIOTECHNOLOGY COMPANY BASED IN SOUTH KOREA. IN JULY 2024, A PHASE 2 PROOF-OF-CONCEPT STUDY WAS INITIATED TO EXPLORE THE USE OF TELACEBEC (Q203) TO TREAT BURULI ULCER. IF SUCCESSFUL, A SINGLE DRUG COULD CUT TREATMENT DURATION BY MORE THAN HALF. IN PARTNERSHIP WITH TB ALLIANCE AND WITH SUPPORT FROM QURIENT CO. LTD, PROFESSOR DANIEL O'BRIEN - A PROMINENT CLINICIAN-RESEARCHER AND EXPERT IN BURULI ULCER - IS LEADING THE STUDY AT BARWON HEALTH AND THE ROYAL MELBOURNE HOSPITAL IN AUSTRALIA. THE TRIAL WILL ENROLL APPROXIMATELY 40 ADULT PATIENTS WITH BURULI ULCER WHO WILL RECEIVE 28 DAYS OF TELACEBEC (300MG) ONCE DAILY, FOLLOWED BY A YEAR OF OBSERVATION. PRELIMINARY RESULTS ARE EXPECTED IN 2025. TBAJ-587 - THIS NEXT-GENERATION DIARYLQUINOLINE PROJECT HAS SHOWN POTENTIAL TO MAINTAIN BEDAQUILINE'S IMPRESSIVE ANTI-TB ACTIVITIES WHILE RETAINING ADDITIONAL IMPROVED PROPERTIES. TBAJ-587 IS BEING STUDIED THROUGH THE INNOVATIVE HEALTH INITIATIVE'S ERA4TB PROJECT AND, IN 2024, TBAJ-587 COMPLETED A PHASE I TRIAL DEMONSTRATING POSITIVE RESULTS. RESULTS PUBLICATIONS ARE UNDERWAY. SUTEZOLID - SUTEZOLID IS A PROMISING CLINICAL-STAGE TB DRUG CANDIDATE FROM THE OXAZOLIDINONE CLASS. TB ALLIANCE HAS IMPLEMENTED AN OPEN DEVELOPMENT APPROACH TO ADVANCE THE PHASE 2 TB DRUG CANDIDATE, SUTEZOLID, WHICH COULD BE A COMPONENT OF A NEXT-GENERATION TB REGIMEN. TB ALLIANCE HAS MADE SUTEZOLID AVAILABLE FOR STUDY BY ALL RESEARCHERS WHO COMMIT TO MAKING THEIR RESULTS AVAILABLE TO THE BROADER TB RESEARCH COMMUNITY. THIS NOVEL APPROACH HAS CONTRIBUTED TO THREE CLINICAL TRIALS THAT BEGAN IN 2023. PEERLINC - IN 2024, TB ALLIANCE LAUNCHED A NEW PEER-TO-PEER LEARNING FOR INNOVATIVE CURES (PEERLINC) KNOWLEDGE HUB BASED IN MANILA, WITH FUNDING FROM THE AUSTRALIAN GOVERNMENT THROUGH THE PARTNERSHIPS FOR A HEALTHY REGION INITIATIVE. PEERLINC, OPERATING IN PARTNERSHIP BETWEEN TB ALLIANCE AND THE TROPICAL DISEASE FOUNDATION, INC. (TDF), AND IN CLOSE COLLABORATION WITH THE DEPARTMENT OF HEALTH (DOH), PHILIPPINES, WILL HELP COUNTRIES IMPLEMENT BEST PRACTICES IN THE TREATMENT OF DRUG-RESISTANT TUBERCULOSIS (DR-TB) TO HELP SPEED THE WORLDWIDE PROGRAMMATIC IMPLEMENTATION OF INNOVATIVE, MORE EFFECTIVE TREATMENTS FOR THE DISEASE, STARTING WITH THE WORLD HEALTH ORGANIZATION (WHO)-RECOMMENDED SIX-MONTH, ALL-ORAL BPAL/M REGIMENS, COMPOSED OF THE ANTIBIOTICS BEDAQUILINE (B), PRETOMANID (PA), AND LINEZOLID (L), WITH OR WITHOUT MOXIFLOXACIN (M). PEERLINC WILL PROVIDE PRACTICAL TRAINING AND TECHNICAL ASSISTANCE TO COUNTRIES TO SUPPORT THIS OBJECTIVE, VIA EXPERTS FROM THE PHILIPPINES AND THE DEPARTMENT OF HEALTH, INCLUDING LUNG CENTER OF THE PHILIPPINES AND THE NATIONAL TB REFERENCE LABORATORY (NTRL). THE PHILIPPINES HAS SUCCESSFULLY AND RAPIDLY DEPLOYED NEW TREATMENTS THROUGH PARTICIPATION IN TB ALLIANCE'S LEVERAGING INNOVATION FOR FASTER TB TREATMENT (LIFT-TB) INITIATIVE. IN 2024 ALONE, THE PEERLINC KNOWLEDGE HUB COMPLETED TRAININGS WITH LEADERS, EXPERTS, AND STAFF FROM NATIONAL TB PROGRAMS IN SEVEN COUNTRIES: PERU, DRC, NIGERIA, BRAZIL, CAMBODIA, TANZANIA, RWANDA. LIFT-TB (LEVERAGING INNOVATION FOR FASTER TREATMENT OF TB) - THIS ACCESS PROGRAM, LAUNCHED IN 2020, SEEKS TO INCREASE TREATMENT COMPLETION RATES FOR DRUG-RESISTANT TB THROUGH ADOPTION AND SCALE UP OF NEW REGIMENS, BEGINNING WITH BPAL. IT FOCUSES ON SEVEN HIGH-BURDEN SOUTHEAST AND CENTRAL ASIAN COUNTRIES THAT SHOULDER APPROXIMATELY 1 IN 5 OF THE GLOBAL TB CASES. AS OF 2024, MORE THAN 100 COUNTRIES HAVE PROCURED THE SIX-MONTH, ALL-ORAL BPAL REGIMEN TO TREAT MORE THAN 180,000 PEOPLE WITH DRUG-RESISTANT TB. FAST TRACK THE CURE - IN SUPPORT OF THE WORLD HEALTH ORGANIZATION'S CALL TO ACTION TO ACCELERATE ACCESS TO SHORTER DR-TB CURES FOR ALL, THE FAST TRACK THE CURE MOVEMENT BRINGS COMMUNITIES AROUND THE WORLD TOGETHER TO RAISE AWARENESS AND FACILITATE ACCESS TO NEW DR-TB TREATMENTS, WHILE RAMPING UP ADVOCACY TO CONVINCE WORLD LEADERS THAT SIX-MONTH DR-TB CURES MUST BE WIDELY ADOPTED AND AVAILABLE TO ALL WHO NEED THEM. FAST TRACK THE CURE IS ALSO COLLABORATING CLOSELY WITH STOP TB TO ENSURE STRATEGIC ALIGNMENT AND PARTNERSHIP AND WITH THE CHALLENGE FACILITY FOR CIVIL SOCIETY MOVEMENT, BY ALIGNING WITH THEIR COMMUNITY ENGAGEMENT, CAPACITY BUILDING, AND DEMAND CREATION PILLARS AND FOCUS. SLASH-TB - TB ALLIANCE AND THE SWISS TROPICAL AND PUBLIC HEALTH INSTITUTE HAVE DEVELOPED SLASH-TB (SAVINGS FROM LEVERAGING & ADOPTING SHORTER & HIGHLY EGGECTIVE TB TREATMENTS), A MODEL TO ESTIMATE COST SAVINGS FOR HEALTH SERVICE SYSTEMS, PATIENTS, FAMILIES, AND/OR CAREGIVERS WHEN USING THE BPAL/M REGIMENS AS COMPARED TO STANDARD DRUG-RESISTANT TB TREATMENTS.

    Expenses $47,923,018

  • PUBLIC AFFAIRS AND POLICY - TB ALLIANCE MAINTAINS CRITICAL ALLIANCES WITH PUBLIC AND PRIVATE ORGANIZATIONS TO RAISE AWARENESS ABOUT TUBERCULOSIS ("TB") AND ADVOCATE FOR PUBLIC AND PRIVATE INVOLVEMENT IN RESEARCH FOR THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY FOR THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR ON THE DEVELOPMENT OF THESE MEDICINES. TB ALLIANCE CONTINUES TO PURSUE AN EXPLICIT COMMITMENT TO OUR "AAA MANDATE" - THAT ALL NEW PRODUCTS WILL BE ADOPTED, AVAILABLE AND AFFORDABLE TO THOSE WITH TB.

    Expenses $5,642,489 · Grants $359,938

  • BUSINESS DEVELOPMENT - TB ALLIANCE NEGOTIATES, IMPLEMENTS AND MANAGES AGREEMENTS WITH PUBLIC AND PRIVATE ORGANIZATIONS WORLDWIDE AND DOES SO BY ADHERING TO SOUND BUSINESS PRACTICES WHILE ENSURING THE PUBLIC GOOD. SPECIFICALLY, TB ALLIANCE NEGOTIATES TERMS THAT SUPPORT THE DEVELOPMENT AND ACCESS OF NEW AFFORDABLE ANTI-TB DRUGS EQUITABLY TO THOSE AREAS MOST IN NEED WHILE ENCOURAGING THE PRIVATE SECTOR TO HELP DEVELOP NEW MEDICINES FOR TB INDICATIONS.

    Expenses $852,237

As filed on the 2024 return.

Officers and directors · 2024

As listed in Part VII of the 2024 return, in the order the filer printed them. Each return names its own; this is not a roster the organization keeps with us.

  • Ariel Pablos-Mendez

    VICE-CHAIR

    Total calculated
    $0
    Hours/week
    3
  • David Norton

    CHAIR

    Total calculated
    $0
    Hours/week
    3
  • Dr Melvin Spigelman

    PRESIDENT/CEO

    Total calculated
    $1,052,936
    From this org
    $939,703
    From related orgs
    $0
    Other
    $113,233
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $664,638
    Bonus
    $275,065
    Other
    $0
    Deferred
    $69,000
    Nontaxable benefits
    $44,233
    Filer's total
    $1,052,936
  • Akshay Vaishnaw

    DIRECTOR (AS OF 12/01/24)

    Total calculated
    $0
    Hours/week
    3
  • Ann Taylor

    DIRECTOR (AS OF 09/01/24)

    Total calculated
    $0
    Hours/week
    3
  • Eric Goosby

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Kim Schwartz

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Mitchell Warren

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Rasha Hibri

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Ratan Watal

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Srishti Gupta

    DIRECTOR (AS OF 12/01/24)

    Total calculated
    $0
    Hours/week
    3
  • Sundar Kodiyalam

    DIRECTOR

    Total calculated
    $0
    Hours/week
    3
  • Angela Vanderploeg

    TREASURER/CFO

    Total calculated
    $526,225
    From this org
    $421,854
    From related orgs
    $0
    Other
    $104,371
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $334,028
    Bonus
    $87,826
    Other
    $0
    Deferred
    $42,395
    Nontaxable benefits
    $61,976
    Filer's total
    $526,225
  • Colleen Pero

    SECRETARY/CAO

    Total calculated
    $541,142
    From this org
    $470,044
    From related orgs
    $0
    Other
    $71,098
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $375,473
    Bonus
    $94,571
    Other
    $0
    Deferred
    $46,106
    Nontaxable benefits
    $24,992
    Filer's total
    $541,142
  • Dr Eugene Sun

    SR. VP, RESEARCH & DEVELOPMENT

    Total calculated
    $674,243
    From this org
    $580,925
    From related orgs
    $0
    Other
    $93,318
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $461,947
    Bonus
    $118,978
    Other
    $0
    Deferred
    $54,642
    Nontaxable benefits
    $38,676
    Filer's total
    $674,243
  • Dr Nader Fotouhi

    SR. VP, CHIEF SCIENTIFIC OFFICER

    Total calculated
    $683,612
    From this org
    $565,207
    From related orgs
    $0
    Other
    $118,405
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $448,750
    Bonus
    $116,457
    Other
    $0
    Deferred
    $56,266
    Nontaxable benefits
    $62,139
    Filer's total
    $683,612
  • Maria Beumont

    VP, CHIEF MEDICAL OFFICER

    Total calculated
    $584,002
    From this org
    $497,709
    From related orgs
    $0
    Other
    $86,293
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $412,534
    Bonus
    $85,175
    Other
    $0
    Deferred
    $46,000
    Nontaxable benefits
    $40,293
    Filer's total
    $584,002
  • Pietro O Turilli

    SR. VP, EXTERNAL AFFAIRS

    Total calculated
    $467,483
    From this org
    $369,474
    From related orgs
    $0
    Other
    $98,009
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $293,361
    Bonus
    $76,113
    Other
    $0
    Deferred
    $36,741
    Nontaxable benefits
    $61,268
    Filer's total
    $467,483
  • Kathleen Schostack

    SR. VP, PROGRAM & ALLIANCE MANAGEMENT

    Total calculated
    $518,559
    From this org
    $432,300
    From related orgs
    $0
    Other
    $86,259
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $343,593
    Bonus
    $88,707
    Other
    $0
    Deferred
    $42,820
    Nontaxable benefits
    $43,439
    Filer's total
    $518,559
  • Rajneesh Taneja

    VP, PHARMACEUTICAL PRODUCT DEVELOPMENT

    Total calculated
    $451,668
    From this org
    $370,728
    From related orgs
    $0
    Other
    $80,940
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $306,440
    Bonus
    $64,288
    Other
    $0
    Deferred
    $36,902
    Nontaxable benefits
    $44,038
    Filer's total
    $451,668
  • Robert Lorette

    SR. VP, BUSINESS DEVELOPMENT

    Total calculated
    $536,240
    From this org
    $448,954
    From related orgs
    $0
    Other
    $87,286
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $357,997
    Bonus
    $90,957
    Other
    $0
    Deferred
    $43,907
    Nontaxable benefits
    $43,379
    Filer's total
    $536,240
  • Salah Foraida

    SR. DIRECTOR, MEDICAL AFFAIRS

    Total calculated
    $482,498
    From this org
    $430,090
    From related orgs
    $0
    Other
    $52,408
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $373,254
    Bonus
    $56,836
    Other
    $0
    Deferred
    $42,937
    Nontaxable benefits
    $9,471
    Filer's total
    $482,498
  • Sandeep Juneja

    SR. VP, MARKET ACCESS

    Total calculated
    $521,229
    From this org
    $417,509
    From related orgs
    $0
    Other
    $103,720
    Hours/week
    45

    Schedule J breakdown matched by us

    Base
    $330,811
    Bonus
    $86,698
    Other
    $0
    Deferred
    $41,851
    Nontaxable benefits
    $61,869
    Filer's total
    $521,229

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us. Earlier years are each on their own filing page.

Filings

  • 2024
    Revenue
    $63,732,557
    Expenses
    $61,508,783
    Contributions
    $52,737,212
    Grants paid
    $359,938
  • 2023
    Revenue
    $60,240,486
    Expenses
    $55,378,579
    Contributions
    $49,796,816
    Grants paid
    $278,450
  • 2022
    Revenue
    $56,212,963
    Expenses
    $55,785,890
    Contributions
    $52,646,326
    Grants paid
    $263,496

The four totals the IRS asks for on Part I of the Form 990, as filed. A dash means the figure was not present on the return — not that it was zero.

Other returns filed

  • 2021 · 990

    Revenue
    $58,653,379
    Expenses
    $57,430,605
    Assets (EOY)
    $187,560,796
  • 2020 · 990

    Revenue
    $61,267,452
    Expenses
    $61,720,389
    Assets (EOY)
    $191,155,661
  • 2019 · 990

    Revenue
    $174,873,899
    Expenses
    $69,535,079
    Assets (EOY)
    $189,418,881
  • 2018 · 990

    Revenue
    $63,283,490
    Expenses
    $60,315,645
    Assets (EOY)
    $75,171,538
  • 2017 · 990

    Revenue
    $58,006,498
    Expenses
    $56,120,604
    Assets (EOY)
    $72,985,406

Nonprofiteer parses Forms 990, 990-EZ and 990-PF, in a window of recent tax years. These returns are recorded from the IRS e-file index, so their figures were extracted by that index rather than read from the return here — treat them as a different source from the filings above, not as more of the same record. A dash means the index carries no figure; Form 990-T listings carry none at all.

Grants made

Where these grants went next →

Grants received

Other IRS files

Auto-Revocation List

Not listed. The IRS publishes this list for organizations whose exemption was automatically revoked for failing to file for three consecutive years.

Publication 78

Listed as of 11 November 2026, under deductibility PC.

These are two separate IRS files on two separate schedules, shown as published and not reconciled with each other. Neither is a statement about whether a contribution is deductible today: 19,245 organizations appear in Publication 78 while the IRS's own revocation file lists them as currently revoked, more than half of those revoked before 2019. Absence from Publication 78 is evidence of nothing, and presence is not evidence either. Verify current status with the IRS before relying on it.

What this page reflects

The registration facts above come from the IRS Business Master File published 9 November 2026 and read 9 November 2026, for every organization at once. Returns through tax year 2024, the newest we have parsed for this organization.